Biotechnology company Soley Therapeutics has raised $200 million Series C financing to advance its proprietary cell stress sensing platform and pipeline of novel therapeutics into clinic. It is believed Soley intends to use the funds to support its work filing investigational new drug (IND) applications and its clinical trials for two first-in-class oncology assets. The […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!